Endovascular Engineering, Inc. (“E2”) has secured $42 million in an oversubscribed Series B financing to advance its next generation clot removal technology platform for venous thromboembolism (VTE).
Read also – Everstar Secures $4Mn in Pre-Seed Funding
The round was co-led by 415 Capital and S3 Ventures, with participation of Panakès Partners, M&L Healthcare, and strong support from founding investor Santé Ventures. Two global strategic investors made substantial commitments alongside Cordis, which continues its strategic partnership with E2.
Read also – Maestro Raises $3Mn in Seed Funding
The capital injection accelerates Endovascular Engineering’s mission to transform VTE treatment, placing an initial focus on advancing novel solutions for addressing Pulmonary Embolism (PE). As the company approaches completing enrollment in its ENGULF pivotal trial to evaluate the Hēlo™ PE Thrombectomy System, the additional capital strengthens E2’s position to address critical unmet needs in interventional medicine while pursuing a new standard of care for both patients and physicians.
“This financing represents more than capital – it validates our technology platform and positions us to revolutionize PE treatment,” said E2’s CEO Dan Rose. “With strong support from sophisticated healthcare investors like 415 Capital and S3 Ventures, we are well-positioned to establish the Hēlo PE System as the gold standard in mechanical thrombectomy for pulmonary embolism.”
“E2 is developing a best-in-class therapy for PE, the third leading cause of cardiovascular death. Its differentiated technology and vision align closely with our mission to advance novel cardiovascular therapies, and we are proud to support E2 as it advances the Hēlo PE thrombectomy platform towards FDA approval,” said Dr. Ruben Osnabrugge, Partner at 415 Capital.
Brian R. Smith, Managing Director at S3 Ventures, said “We are truly impressed by E2’s next- generation platform technology for VTE and see this as a solution to dramatically scale the mechanical thrombectomy market and improve the lives of patients.”
The company also announced the appointment of Dr. Osnabrugge of 415 Capital and Mr. Brian R. Smith of S3 Ventures to its board of directors.
About Endovascular Engineering
Endovascular Engineering, Inc. (“E2”), is at the forefront of transforming venous thromboembolism (VTE) treatment. As a venture-backed medical technology innovator, E2 is dedicated to developing and deploying groundbreaking solutions that advance the standard of care in clot removal. The company’s technology platform represents the convergence of clinical insight and engineering excellence, aimed at addressing the complex challenges in VTE intervention.
